Cyteir Therapeutics, Inc. CYTT
3.01
0.00
0.00%
as of 31 May
- Market cap
- $108.7M
- P/E
- 0.0×
Follow CYTT
Growth Flags
show if company had growth for consecutive years
| Dec '17 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | |
|---|---|---|---|---|---|
P/E ratio |
— | 0.00 | — | — | — |
P/S ratio |
— | 0.00 | — | — | — |
P/FCF ratio |
— | 0.00 | — | — | — |
P/Operating CF |
— | (5.88) | — | — | — |
P/B ratio |
— | 0.20 | — | — | — |
Price to Tangible BV |
— | 0.20 | — | — | — |
EV/Sales |
— | 0.00 | — | — | — |
EV/EBITDA |
— | 6.73 | — | — | — |
EV/Operating CF |
— | 6.11 | — | — | — |
EV/FCF |
— | 5.87 | — | — | — |
Quick Ratio |
— | 14.71 | 3.49 | 25.26 | 27.68 |
Current Ratio |
— | 15.43 | 3.87 | 25.71 | 28.07 |
Net Debt/EBITDA |
— | 1.83 | 0.53 | 4.54 | 3.10 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
— | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
— | 1.17 | 0.89 | 0.86 | 0.92 |
Capex/Depreciation |
— | 0.00 | (2.42) | (2.48) | (0.47) |
Interest Coverage |
— | 0.00 | 0.00 | 0.00 | 0.00 |
| — | 39.40% | 54.53% | (60.50%) | (27.62%) | |
| — | (95.92%) | (92.33%) | (40.29%) | (26.42%) | |
ROIC |
— | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
— | (51.43%) | (202.54%) | (22.45%) | (31.64%) |
Average Days of Receivables |
— | 0.00 | — | — | — |
Research and Development Expense of Revenue |
— | 159,600.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
— | 39,125.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
— | 4.94 | — | — | — |
Graham Number |
— | 0.00 | — | — | — |
Earnings Yield |
— | (64.65%) | — | — | — |
Free Cash Flow Yield |
— | (69.25%) | — | — | — |
Revenue per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
— | (3.99) | (12.11) | (1.85) | (1.21) |
Capex per Share |
— | 0.00 | (0.56) | (0.06) | (0.01) |
Free Cash Flow per Share |
— | (3.99) | (12.66) | (1.91) | (1.21) |
Cash per Share |
— | 6.60 | 7.14 | 9.73 | 4.17 |
Shareholders Equity per Share |
— | 6.61 | (31.37) | 9.61 | 4.15 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | 6.61 | (31.37) | 9.61 | 4.15 |
Free Cash Flow |
— | (17.56) | (19.39) | (37.22) | (42.84) |
Working Capital |
— | 28.47 | 8.99 | 185.57 | 143.89 |
Capital Expenditures |
— | (0.13) | (0.85) | (1.19) | (0.31) |
Net Current Asset Value |
— | 28.14 | (49.63) | 184.98 | 142.26 |
EV/EBIT |
— | 0.00 | — | — | — |
Capex to Sales |
— | 0.00 | 0.00 | 0.00 | 0.00 |
Net Profit Margin |
— | (188,050.00%) | 0.00% | 0.00% | 0.00% |
Price to Operating Income |
— | 0.00 | — | — | — |
| Other line items | |||||
Depreciation/Fixed assets |
— | 0.27 | 0.27 | 0.23 | 0.39 |
Cash ROIC |
— | (31.58%) | 53.45% | (10.10%) | (15.08%) |
Accounts Receivable Turnover |
— | 0.00 | — | — | — |
Accounts Payable Turnover |
— | 0.19 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
— | 1,022.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | 0.00 | 0.00 | 0.00 | 0.00 |
Average Payables |
— | 1.15 | 1.15 | 1.74 | 1.46 |
Average Assets |
— | 15.68 | 22.55 | 104.56 | 174.31 |
Average Common Equity |
— | (38.18) | (38.18) | 69.63 | 166.79 |
Columns are period end dates